HOOKIPA PHARMA INC (HOOK) Stock Price, Quote, News and Overview
NASDAQ:HOOK - Nasdaq - US43906K2096 - Common Stock - Currency: USD
HOOK Quote, Performance and Key Statistics
NASDAQ:HOOK (5/5/2025, 9:47:29 AM)
1.32
-0.02 (-1.49%)
The current stock price of HOOK is 1.32 USD. In the past month the price increased by 57.55%. In the past year, price decreased by -85.59%.
HOOK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.17 | 348.35B | ||
| AMGN | AMGEN INC | 13.35 | 149.04B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1727.52 | 128.79B | ||
| GILD | GILEAD SCIENCES INC | 13.29 | 128.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.64 | 65.27B | ||
| ARGX | ARGENX SE - ADR | 344.02 | 39.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.07B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.18B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.65B | ||
| NTRA | NATERA INC | N/A | 21.17B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.37B | ||
| BIIB | BIOGEN INC | 7.75 | 17.97B |
Related stock screener links
About HOOK
Company Profile
HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The company is headquartered in New York City, New York and currently employs 82 full-time employees. The company went IPO on 2019-04-18. The Company’s product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. Its two primary programs include HB-700 and Eseba-vec. HB-700 is a multi-KRAS mutant-targeting, investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Eseba-vec is an investigational immunotherapeutic agent in clinical development for the treatment of HPV16+ head and neck cancers. The firm has partnered with Gilead Sciences, Inc. to develop therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1.
Company Info
HOOKIPA PHARMA INC
350 Fifth Avenue, 72Nd Floor, Suite 7240
New York City NEW YORK 10118 US
CEO: Joern Aldag
Employees: 85
Phone: 114318906360
HOOKIPA PHARMA INC / HOOK FAQ
What is the stock price of HOOKIPA PHARMA INC today?
The current stock price of HOOK is 1.32 USD. The price decreased by -1.49% in the last trading session.
What is the ticker symbol for HOOKIPA PHARMA INC stock?
The exchange symbol of HOOKIPA PHARMA INC is HOOK and it is listed on the Nasdaq exchange.
On which exchange is HOOK stock listed?
HOOK stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for HOOKIPA PHARMA INC stock?
9 analysts have analysed HOOK and the average price target is 25.25 USD. This implies a price increase of 1812.5% is expected in the next year compared to the current price of 1.32. Check the HOOKIPA PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is HOOKIPA PHARMA INC worth?
HOOKIPA PHARMA INC (HOOK) has a market capitalization of 15.92M USD. This makes HOOK a Nano Cap stock.
How many employees does HOOKIPA PHARMA INC have?
HOOKIPA PHARMA INC (HOOK) currently has 85 employees.
What are the support and resistance levels for HOOKIPA PHARMA INC (HOOK) stock?
HOOKIPA PHARMA INC (HOOK) has a resistance level at 1.35. Check the full technical report for a detailed analysis of HOOK support and resistance levels.
Is HOOKIPA PHARMA INC (HOOK) expected to grow?
The Revenue of HOOKIPA PHARMA INC (HOOK) is expected to decline by -60.79% in the next year. Check the estimates tab for more information on the HOOK EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy HOOKIPA PHARMA INC (HOOK) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of HOOK, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of HOOK, evaluating the profitability, health, valuation and growth aspects
- HOOKIPA PHARMA INC (HOOK) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- HOOKIPA PHARMA INC (HOOK) Sales and EPS estimates to see what analysts future expectations are.
- HOOKIPA PHARMA INC (HOOK) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- HOOKIPA PHARMA INC (HOOK) Insider and Institutional Ownership to learn about the owners and their transactions.
- HOOKIPA PHARMA INC (HOOK) Stock Chart to make your own analysis
- HOOKIPA PHARMA INC (HOOK) Latest news and press-releases to stay up to date.
Does HOOKIPA PHARMA INC (HOOK) stock pay dividends?
HOOK does not pay a dividend.
When does HOOKIPA PHARMA INC (HOOK) report earnings?
HOOKIPA PHARMA INC (HOOK) will report earnings on 2025-05-07.
What is the Price/Earnings (PE) ratio of HOOKIPA PHARMA INC (HOOK)?
HOOKIPA PHARMA INC (HOOK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.51).
What is the Short Interest ratio of HOOKIPA PHARMA INC (HOOK) stock?
The outstanding short interest for HOOKIPA PHARMA INC (HOOK) is 0.14% of its float. Check the ownership tab for more information on the HOOK short interest.
HOOK Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to HOOK. When comparing the yearly performance of all stocks, HOOK is a bad performer in the overall market: 96.14% of all stocks are doing better.
HOOK Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to HOOK. While HOOK seems to be doing ok healthwise, there are quite some concerns on its profitability.
HOOK Financial Highlights
Over the last trailing twelve months HOOK reported a non-GAAP Earnings per Share(EPS) of -3.51. The EPS increased by 60.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -52.7% | ||
| ROE | -84.94% | ||
| Debt/Equity | 0 |
HOOK Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to HOOK. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 26.59% and a revenue growth -60.79% for HOOK